1. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma 
Nicolaus Kröger, Jose A. Perez-Simon, Han Myint, Hans Klingemann, Avichai Shimoni, Arnon Nagler, Rodrigo Martino, Adrian Alegre, Jose F. Tomas, Rainer Schwerdtfeger, Michael Kiehl, Axel Fauser, Herbert Gottfried Sayer, Angel Leon, Jörg Beyer, Tatjana Zabelina, Francis Ayuk, Jesus F. San Miguel, Ronald Brand, Axel Rolf Zander 
Biology of Blood and Marrow Transplantation 
Volume 10, Issue 10, Pages (October 2004)
DOI: /j.bbmt

2. Figure 1 Treatment protocols and number of patients included.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )

3. Figure 2
Cumulative incidence of relapse and treatment-related mortality in patients with (right) or without (left) relapse to a prior autograft.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )

4. Figure 3
Overall survival according to relapse with prior high-dose chemotherapy.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )